REFERENCES
- Friedman AJ. Treatment of uterine myomas with GnRH agonists. Sem Reprod Endocrinol 1993;11:154–61
- Broekmans FJ. GnRH agonists and uterine leiomyoma. Hum Reprod 1996;11\(suppl. 3):3–25
- Mizutani T, Sugihara A, Nakamuro K, et al. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leu-prolide acetate). J Clin Endocrinol Metab 1998;83:1253–5
- Gerdes J, Li L, Schlueter C, et al. Immunohistochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867–73
- Gattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357–63
- Vu K, Greenspan DL, Wu T-C, et al. Cellular proliferation, estrogen receptor, progesterone receptor, and bc1-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998;29: 359–63
- Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohisto-chemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844–50
- West CP, Lumsden MA, Hillier H, et al. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod 1992;7:328–332
- Schiff I, Tulchinsky D, Cramer D, et al. Oral medroxypro-gesterone in the management of postmenopausal symptoms. JAMA 1980;244:1443–5
- Mandel FP, Davidson BJ, Erlik Y, et al. Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med 1982;27:511–4
- Friedman AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study. Fertil Steril 1989;51:526–8
- Hoshimoto K, Hayashi M, Ohkura T. Regulation of dosage of conjugated equine estrogen is useful for add-back therapy. J Med 2000;31:167–75